Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 42.50
Bid: 42.00
Ask: 43.00
Change: 2.10 (5.20%)
Spread: 1.00 (2.381%)
Open: 42.75
High: 42.75
Low: 41.00
Prev. Close: 40.40
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directors Dealings

24 Feb 2014 07:00

RNS Number : 6954A
Avacta Group PLC
24 February 2014
 

24 February 2014

Avacta Group plc

("Avacta" or the "Group")

 

Directors' Dealings

 

The Group announces the following changes to the equity incentives of its Non-Executive Chairman, Trevor Nicholls, and its Chief Operating Officer, Craig Slater.

 

Trevor Nicholls

On his appointment to the Board of Avacta on 2 August 2013, Dr Nicholls was awarded options over 5,454,545 ordinary shares of 0.1p each in the Group ("Ordinary Shares"). In order to pursue best corporate governance practice, the Avacta Board has agreed with Dr Nicholls that 3,500,000 of those options should vest conditional upon Dr Nicholls exercising those options immediately and conditional upon it being agreed by Dr Nicholls that the balance of 1,954,545 options over Ordinary Shares be cancelled with immediate effect. Dr Nicholls has agreed to that conditionality and therefore the options over 3,500,000 Ordinary Shares have vested and Dr Nicholls has exercised his option over those Ordinary Shares. 

 

The exercise price of each option is 0.55 pence per share and, following exercise, Dr Nicholls is now interested in a total of 3,500,000 ordinary shares of 0.1p each in the Group, representing approximately 0.1% of the Group's issued share capital.

 

Dr Nicholls no longer holds any options over ordinary shares in Avacta.

 

Application will be made for the 3,500,000 new Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on 28 February 2014.

 

The total number of Ordinary Shares in issue following the above issue will be 4,026,051,956 each with voting rights. No Ordinary Shares are held in Treasury.

 

The above figure of 4,026,051,956 shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Group under the FCA's Disclosure and Transparency Rules.

 

Craig Slater

On 21 February 2014, Mr Slater was granted options over 20,000,000 Ordinary Shares pursuant to the Avacta Group Enterprise Management Incentive ("EMI") Scheme. The option exercise price is 1.18p per share and the options vest as follows:

 

- 5,000,000 options over Ordinary Shares vest on 23 December 2014

- 5,000,000 options over Ordinary Shares vest on 23 December 2015

- 5,000,000 options over Ordinary Shares vest on 23 December 2016

- 5,000,000 options over Ordinary Shares vest on 23 December 2017

 

In addition, on 21 February 2014 Mr Slater purchased an interest in 34,082,086 existing Ordinary Shares at a price of 1% of 1.18 pence per share, in accordance with the terms of the Avacta Joint Share Ownership Plan (the "Joint Share Ownership Plan") established on 9 January 2012. This interest is joint with Avacta Group Trustee Limited as trustee for the Avacta Group Employee's Share Trust under the Joint Share Ownership Plan. Following this purchase, Mr Slater has an interest in 34,082,086 Ordinary shares, representing approximately 0.8% of the Group's issued share capital.

 

 

Enquiries:

 

Avacta Group plc

Tel: +44 (0) 844 414 0452

Alastair Smith, Chief Executive Officer

www.avacta.com

Tim Sykes, Chief Financial Officer

Numis Securities Limited

Tel: +44 (0) 207 260 1000

Michael Meade / Freddie Barnfield - Nominated Adviser

www.numiscorp.com

James Black - Corporate Broking

Walbrook PR Ltd

Tel: +44 (0) 20 7933 8780 or avacta@walbrookpr.com

Anna Dunphy

Mob: +44 (0)7876 741 001

Lianne Cawthorne

Mob: +44 (0)7584 391 303

 

 

About Avacta Group plc - www.avacta.com

 

Avacta Group plc is a global provider of innovative technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics. Avacta operates through three divisions:

 

Avacta Analytical

www.avactaanalytical.com

 

High throughput analysis instrument, Optim, to help reduce the cost and risk of drug development.

Avacta Animal Health

www.avactaanimalhealth.com

 

Veterinary diagnostics reference laboratory, diagnostic kits and newly launched in-clinic blood analyser, Sensipod.

Avacta Life Sciences

www.avactalifesciences.com

 

Novel non-antibody affinity reagents called Affimers, with a wide range of Life Science applications in diagnostics, drug and biomarker discover and biotech research and development.

 

Avacta joined AIM in August 2006 and is based in Wetherby, England.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSLFFSLFRILFIS
Date   Source Headline
10th Oct 20177:00 amRNSAvacta to Present at Major US Conference
9th Oct 20174:02 pmRNSDirector Dealing and Issue of Equity
5th Oct 20177:00 amRNSResearch collaboration with FIT Biotech Oy
4th Oct 20177:00 amRNSPreliminary Results
2nd Oct 20177:00 amRNSAvacta establishes US business development team
7th Sep 20177:00 amRNSNotice of Results
21st Aug 201712:00 pmRNSDirector/PDMR Shareholding
7th Aug 20177:00 amRNSTrading Update
31st Jul 201712:00 pmRNSIssue of Equity
28th Jul 20171:15 pmRNSDirector/PDMR Shareholding
5th Jul 20177:00 amRNSDirector Dealing and Issue of Equity
4th Jul 20177:00 amRNSManchester ShareSoc Growth Company Seminar
5th Jun 20177:00 amRNSShareSoc Growth Company Seminar
1st Jun 20178:56 amRNSIssue of Equity
22nd May 20177:00 amRNS2 Biotech's Licence Affimers for Research Use
10th May 20177:00 amRNSKey Affimer Patent To Be Granted in China
8th May 20171:21 pmRNSHardman Research: De-risking Moderna's partnership
5th May 20177:00 amRNSPresenting at the Hardman Private Investor Forum
2nd May 20177:00 amRNSAvacta to Present at BioTrinity 2017
24th Apr 20177:00 amRNSDiagnostics firm take rights to several Affimers
19th Apr 20177:00 amRNSAvacta to Present at the Shares Spotlight Evening
12th Apr 20177:15 amRNSHardman Research: Another important box ticked
6th Apr 20172:23 pmRNSHolding(s) in Company
6th Apr 20172:23 pmRNSHolding(s) in Company
6th Apr 201710:22 amRNSDirector/PDMR Shareholding
3rd Apr 20177:00 amRNSInterim Results for the Period Ended 31 Jan 2017
3rd Apr 20177:00 amRNSResults of Immunogenicity Study with Human Samples
31st Mar 20179:31 amRNSAvacta Presents at Investor Evening Hosted by TPI
31st Mar 20177:00 amRNSLondon Growth and Innovation Forum Presentation
22nd Mar 20179:00 amRNSAvacta to present at the UK Investor Show
21st Mar 20177:15 amRNSHardman Research: Low response would be positive!
30th Jan 20177:00 amRNSDirector/PDMR Shareholding
20th Jan 201711:35 amRNSResult of Annual General Meeting
20th Jan 20177:00 amRNSTrading Update
11th Jan 20177:00 amRNSPresenting at London Growth and Innovation Forum
5th Jan 20177:00 amRNSDirector Dealing and Issue of Equity
20th Dec 20167:00 amRNSDirector/PDMR Shareholding
16th Dec 20165:14 pmRNSHolding(s) in Company
1st Dec 20167:00 amRNSNotice of AGM, Accounts and Directorate Change
23rd Nov 20167:00 amRNSTechnical Update: Affinity Separation
7th Nov 20167:00 amRNSCancer Expert joins Scientific Advisory Board
2nd Nov 20167:00 amRNSCAR-T Cell Therapy Research Collaboration in US
1st Nov 20167:00 amRNSResults from first Affimer pre-clinical studies
21st Oct 201611:39 amRNSDirector's Dealing
17th Oct 20161:00 pmRNSHardman Research: Great strides to strategic goals
17th Oct 20167:00 amRNSPrelim Results for the Year Ended 31 July 2016
4th Oct 20163:28 pmRNSIssue of Equity
26th Sep 201611:21 amRNSNotice of Results
22nd Sep 20167:00 amRNSPositive results from first preclinical studies
12th Sep 20167:00 amRNSChange of Adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.